SCOTT GEOFFREY GATES sold $2.6M of AEHR (indirect holdings)

SCOTT GEOFFREY GATES (Director) sold 20,000 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $131.51 ($2.63M total) on 2026-08-12.

Original reporting
SEC EDGAR · SCOTT GEOFFREY GATES
Published Aug 13, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and post-transaction holdings. It may slightly pressure sentiment, but it is not a guidance, earnings, or operational catalyst.

02

Market read

Traders may monitor AEHR for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without additional company news.

03

What to watch

The article provides no context on total holdings, prior sale cadence, or whether the sale was for diversification or tax obligations, limiting signal strength.

Relevance 6/10Novelty 5/10Timing: after-hours/next-session following the Form 4 filing date (2026-08-13)

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR Test Systems, filed by director Scott Geoffrey Gates.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Scott Geoffrey Gates sold 20,000 shares in an open-market transaction valued at $2.63M, per a fresh Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

This is a routine Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific operational or financial disclosure in the text.

Market effects

No sector-wide read-through is provided; the disclosure is company-specific and small relative to typical sector flows.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for liquidity or tax needs; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • AEHR Test Systems

    Company whose director insider sale is disclosed via Form 4.

  • Scott Geoffrey Gates

    Director reporting an open-market sale of AEHR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.